TG Therapeutics signs $645M deal to kick-start international launch of MS antibody

TG Therapeutics is looking to expand access to its CD20 antibody Briumvi outside North America and has announced a partnership with the European pharma company Neuraxpharm.

The deal is for $140 million in cash upfront, plus another $12.5 million once the drug, approved in the US and EU for adults with relapsing forms of multiple sclerosis, is launched in the first EU member country, according to a press release Tuesday.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Preventing the spread of superbugs in aged care facilities

There’s an urgent need for more careful antibiotic management to protect older people living in residential aged care from the dangerous spread of antibiotic-resistant bacteria

August 29, 2024

Here Are This Year’s Best Employers in Healthcare and Biotech

Forbes has rolled out its annual rankings of America’s top employers, and a bevy of healthcare companies have made the cut. Novo Nordisk — recently

February 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.